The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series A - IV | Alive

Total Raised


Last Raised

$10M | 2 yrs ago

About Orbus Therapeutics

Orbus Therapeutics is a private, clinical-stage biopharmaceutical company is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The Company's product candidate in clinical development is eflornithine. Eflornithine is a cytostatic agent, which the Company is developing to treat patients with recurrent anaplastic astrocytoma (rAA), a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain types of cancer.

Orbus Therapeutics Headquarter Location

2479 East Bayshore Road Suite 105

Palo Alto, California, 94303,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Orbus Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Orbus Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Orbus Therapeutics Patents

Orbus Therapeutics has filed 5 patents.

The 3 most popular patent topics include:

  • Brain tumor
  • Oncology
  • Cerebrum
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Brain tumor, Prodrugs, Oncology, MicroRNA


Application Date


Grant Date



Related Topics

Transcription factors, Brain tumor, Prodrugs, Oncology, MicroRNA



Latest Orbus Therapeutics News

Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment

Jan 19, 2022

- Pre-specified interim analysis to test for superiority expected to occur in 2022 - PALO ALTO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced that patient enrollment of its Phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma is complete. The STELLAR study completed full enrollment with a total of 343 patients. “We are delighted to announce that we have completed enrollment of patients in the STELLAR study. The STELLAR study is the largest randomized Phase 3 study that has been conducted in this patient population,” said Bob Myers, co-founder and CEO. “This achievement represents an important milestone for our company toward our goal of bringing this new potential therapy to patients with recurrent anaplastic astrocytoma, a rare and fatal disease. We look forward to conducting an interim analysis for superiority in 2022.” About the STELLAR study The STELLAR study, a Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine and Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy, started in late 2016 and has involved more than 85 leading clinical trial centers in eight countries in North America and Europe. The trial is designed to evaluate the efficacy and safety of eflornithine in combination with lomustine compared to lomustine alone in patients with anaplastic astrocytoma that recurs after surgery, irradiation and adjuvant temozolomide chemotherapy. The primary efficacy endpoint in the STELLAR study is the duration of overall survival (OS). Secondary pre-specified efficacy endpoints include OS in isocitrate dehydrogenase (IDH) mutant and wild type sub-populations, progression free survival (PFS) and objective response rate (ORR). Find more information about the STELLAR study here . About Anaplastic Glioma and Anaplastic Astrocytoma Several brain tumor types are grouped together under the name glioma which originates in the glial cells that surround and support neurons in the brain. In the United States, greater than 2,000 new cases of anaplastic glioma, one of three grades of malignant glioma, are diagnosed each year. Despite treatment with surgery, radiation and chemotherapy, median survival for people with anaplastic glioma is just over three years. Anaplastic astrocytoma is the largest subset of anaplastic glioma, and represents approximately 75 percent of anaplastic glioma patients. Anaplastic astrocytomas typically require aggressive treatment and, due to tentacle-like projections that grow into surrounding tissue, are difficult to completely remove during surgery. It is estimated that there are more than 1,500 new anaplastic astrocytoma cases diagnosed in the United States each year. The prevalence of diffuse and anaplastic astrocytoma in the United States is estimated to be just over 23,000 people. About Eflornithine Eflornithine is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain types of cancer. In controlled, randomized and single arm clinical studies, eflornithine has shown an increase in overall survival of patients with newly diagnosed or recurrent anaplastic astrocytoma. Eflornithine has been granted Orphan Drug Designation and Breakthrough Therapy Designation for the treatment of patients with anaplastic glioma by the U.S. Food and Drug Administration (FDA), and has also been granted Orphan Medicinal Product status for the treatment of glioma by the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA). About Orbus Therapeutics Orbus Therapeutics Inc. is a late-stage, private biopharmaceutical company that is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The Company’s lead product candidate, eflornithine, is being evaluated in a pivotal Phase 3 clinical trial in patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. For more information, please visit the Company's website at Source: Orbus Therapeutics, Inc.

Orbus Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Orbus Therapeutics Rank

  • Where is Orbus Therapeutics's headquarters?

    Orbus Therapeutics's headquarters is located at 2479 East Bayshore Road, Palo Alto.

  • What is Orbus Therapeutics's latest funding round?

    Orbus Therapeutics's latest funding round is Series A - IV.

  • How much did Orbus Therapeutics raise?

    Orbus Therapeutics raised a total of $71M.

  • Who are the investors of Orbus Therapeutics?

    Investors of Orbus Therapeutics include Longitude Capital, H.I.G. BioHealth Partners, Adams Street Partners, Abingworth, Pappas Ventures and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.